COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

Completed · Phase 1/Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.

Key facts

Study ID

NCT00004147

Run by

New Approaches to Brain Tumor Therapy Consortium

Starts

2000-07-01

Expected to finish

2006-11-01

Last updated by the study team

2013-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Emory University Hospital - Atlanta — Atlanta, Georgia, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.